Hippocrates Research S.r.l.
Corporate brand
UnclaimedItalian contract research organization (CRO) specializing in rare diseases, orphan drugs, first-in-human studies and advanced therapies.
Last updated September 28, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Hippocrates Research S.r.l. (HR) is an Italian contract research organization (CRO) based in Genoa, with an additional presence in Lugano, Switzerland. It operates as the clinical research arm of the Hippocrates Group and provides end-to-end services across the full drug development lifecycle, from early clinical development to post-marketing studies. The company positions itself as a best-in-class, full-service CRO with particular expertise in rare diseases, orphan drugs, first-in-human studies and advanced therapies, alongside deep knowledge of the European regulatory framework. HR's service portfolio covers Phase I through Phase IV clinical trials, including non-interventional studies (NIS) and post-authorization safety studies (PASS). The company offers digital and decentralized clinical trial capabilities such as e-CRF, e-TMF and e-PRO, remote monitoring, pragmatic trials, and full statistical and data management services. It also provides market access advisory, regulatory affairs, quality assurance, medical affairs, scientific communication and real-world evidence (RWE) through the complementary expertise of the wider Hippocrates Group. The group structure supports international trial expansion, allowing sponsors to scale clinical programs across multiple geographies. Hippocrates Research serves customers across Europe (57%), Italy (30%), and North America and Japan (13%). The company is privately owned by a team of experienced clinical research professionals and reports being debt-free. It emphasizes an agile organizational structure with fast and flexible decision-making, a customer retention rate of 84% by value, and a highly trained workforce that is 90% women and 95% graduates, with an employee turnover of 2.6% for 2023–2025, described as ten times lower than the European industry average. Regulatory and quality credentials include qualification by AIFA, EMA and ENCePP, ISO 9001:2015 and ISO UNI PDR 125:2022 certification, EcoVadis rating, SIMeF–GIQAR affiliation, full GDPR compliance with an independent Data Protection Officer, and membership in the UN Global Compact. The management team brings over 30 years of pharmaceutical industry experience, organized into dedicated research units and supported by structured national and international training programs.
History
Hippocrates Research S.r.l. is a contract research organization (CRO) based in Genoa, Italy, operating within the Hippocrates Group. The company was established to provide clinical research services to the pharmaceutical and biotechnology industries, with a focus on complex and specialized therapeutic areas. While the exact founding year is not specified in the available sources, the management team is described as bringing over 30 years of experience in the pharmaceutical industry, indicating a leadership with deep sector roots. From its base in Genoa, with an additional presence in Lugano, Switzerland, Hippocrates Research has grown into a full-service CRO supporting sponsors across the entire product development lifecycle, from early clinical development to product launch. The company has built particular expertise in rare diseases, orphan drugs, first-in-human studies and advanced therapies, and has developed a deep knowledge of the European regulatory framework. Its service offering has expanded to include digital and decentralized clinical trials, remote monitoring, pragmatic trials, and full statistical and data management services. A key element of the company's development has been its integration within the Hippocrates Group, which allows it to leverage complementary expertise in medical affairs, regulatory affairs, quality assurance, clinical operations, market access advisory, scientific communication and real-world evidence. This group structure also supports international trial expansion, enabling sponsors to scale clinical programs across multiple geographies. Hippocrates Research reports serving customers across Europe (57%), Italy (30%), and North America and Japan (13%). The company has obtained regulatory qualifications from AIFA, EMA and ENCePP, and holds ISO 9001:2015 and ISO UNI PDR 125:2022 certifications. It is EcoVadis rated, affiliated with SIMeF–GIQAR, fully GDPR compliant with an independent Data Protection Officer, and a member of the UN Global Compact. Hippocrates Research is privately owned by a team of experienced clinical research professionals, is debt-free, and reports a customer retention rate of 84% by value. Its workforce is 90% women and 95% graduates, with an employee turnover of 2.6% for 2023–2025, described as ten times lower than the European industry average.
Hippocrates Research operates as a CRO within the Hippocrates Group, based in Genoa, Italy.
Company reports employee turnover of 2.6% for 2023–2025, described as ten times lower than the European industry average.
Hippocrates Research is qualified by AIFA, EMA and ENCePP.
Company holds ISO 9001:2015 and ISO UNI PDR 125:2022 certifications, is EcoVadis rated, and is a UN Global Compact member.
Products and positioning
Best-in-class, full-service CRO with agile decision-making, strong European regulatory expertise, and a focus on rare diseases and advanced therapies.
Phase I–IV clinical trial management
End-to-end support across all phases of clinical research, from early clinical development to post-marketing activities.
Non-interventional studies (NIS) and post-authorization safety studies (PASS)
Strong capabilities in post-marketing and observational studies across all therapeutic areas.
Digital and decentralized clinical trials
Includes e-CRF, e-TMF, e-PRO, remote monitoring, and pragmatic trials.
Statistical and data management services
Full statistical and data management services integrated into clinical trial workflows.
Regulatory affairs and quality assurance
Deep knowledge of the European regulatory framework and strong quality assurance competence.
Market access advisory and real-world evidence (RWE)
Provided through the complementary expertise of the Hippocrates Group.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/hippocrates-research-srl-italy · Editorial policy · How profiles are compiled